129
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

[211At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies

, , , , , , , , , & ORCID Icon show all
Pages 1335-1339 | Received 07 Mar 2023, Accepted 19 Apr 2023, Published online: 11 May 2023
 

Disclosure statement

All authors declare no competing conflict of interest.

Data availability statement

For original data and reagents, please contact the corresponding author ([email protected]).

Additional information

Funding

Research reported in this publication was supported by the National Institutes of Health/National Cancer Institute (NIH/NCI; R01-CA172582).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.